Dosage ; Major depressive disorder: Initial and maintenance dose: 60 mg/day. Diabetic peripheral neuropathic pain: 60-120 mg/day.
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Cymbalta | Eli Lilly & Co. | Statim Pharmaceuticals Ltd | 30mg | 28 | Capsule | per capsule | KES 4,584.00 |
| Cymbalta | Eli Lilly & Co. | Statim Pharmaceuticals Ltd | 60mg | 28 | Capsule | per capsule | KES 4,584.00 |
| Duocip | Cipla Ltd. | Lords Healthcare Ltd. | 30mg | 30 | Capsule | per capsule | KES 1,610 |
| Duocip | Cipla Ltd. | Lords Healthcare Ltd. | 60mg | 30 | Capsule | per capsule | KES 2,760 |
| Duzela | Sun Pharmaceuticals Ltd | Sunpar Pharmaceuticals Ltd. | 20mg | 30 | Capsule | per capsule | KES 1,200.00 |
| Duzela | Sun Pharmaceuticals Ltd | Sunpar Pharmaceuticals Ltd. | 30mg | 30 | Capsule | per capsule | KES 1,650.00 |
| Duzela | Sun Pharmaceuticals Ltd | Sunpar Pharmaceuticals Ltd. | 60mg | 30 | Capsule | per capsule | KES 2,850.00 |
|
Duloxetine More info |
|
|---|---|
| Mode Of Action | Combined serotonin (5-HT) and noradrenaline (NA) re-uptake inhibitor e.g. Duloxetine |
| Drug Indication | Major depressive disorder. Management of neuropathic pain associated with diabetic peripheral neuropathy in adults. |
| Precautions | History of mania/hypomania, seizures, renal impairment, concomitant use with antidepressants, elderly, liver transaminase elevations. May impair ability to drive or use machines, pregnancy and lactation. |
| Contra-Indications | Hypersensitivity to duloxetine HCl or to any of the excipients of the formulation. Concomitant use of duloxetine with nonselective, irreversible MAOIs. Liver disease resulting in hepatic impairment. Use in combination with fluvoxamine, ciprofloxacin or enoxacine (ie, potent CYP1A2 inhibitors) since the combination results in elevated plasma concentrations of duloxetine. Severe renal impairment (creatine clearance <30 ml/min). Uncontrolled narrow-angle glaucoma. |
| Side Effects | GI disorders, excessive sweating, CNS disorders like dizziness, fatigue, insomnia, somnolence, blurred vision, dysuria. |
| Dosage | Major depressive disorder: Initial and maintenance dose: 60 mg/day. Diabetic peripheral neuropathic pain: 60-120 mg/day. |
| Drug Category | DRUGS ACTING ON CNS |
| Drug Sub-Category | Antidepressants, anxiolytics
Dosing: Adult Major depressive disorder: Oral: Initial: 40-60 mg/day; dose may be divided (ie, 20 or 30 mg twice daily) or given as a single daily dose of 60 mg; maintenance: 60 mg once daily; for doses >60 mg/day, titrate dose in increments of 30 mg/day over 1 week as tolerated to a maximum dose: 120 mg/day. Note: Doses >60 mg/day have not been demonstrated to be more effective. Diabetic neuropathy: Oral: 60 mg once daily; lower initial doses may be considered in patients where tolerability is a concern and/or renal impairment is present. Note: Doses up to 120 mg/day administered in clinical trials offered no additional benefit and were less well tolerated than dose of 60 mg/day. Fibromyalgia: Oral: 30 mg once daily for 1 week, then increase to 60 mg once daily as tolerated. Note: Doses up to 120 mg/day administered in clinical trials offered no additional benefit and were less well tolerated than dose of 60 mg/day. Generalized anxiety disorder: Oral: Initial: 30-60 mg/day as a single daily dose; patients initiated at 30 mg/day should be titrated to 60 mg/day after 1 week; maximum dose: 120 mg/day. Note: Doses >60 mg/day have not been demonstrated to be more effective than 60 mg/day. Chronic musculoskeletal pain: Oral: 30 mg once daily for 1 week, then increase to 60 mg once daily as tolerated Stress incontinence (unlabeled use): Oral: 40 mg twice daily (Dmochowski, 2003) Note: Upon discontinuation of duloxetine therapy, gradually taper dose. If intolerable symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate. Dosing: Geriatric Major depressive disorder: Oral: Manufacturer does not recommend specific dosage adjustment. Conservatively, may initiate at a dose of 20 mg 1-2 times/day; increase to 40-60 mg/day as a single daily dose or in divided doses or initiate therapy at 30 mg/day for 1 week then increase to 60 mg/day as tolerated. Other indications: Refer to adult dosing. Dosing: Renal Impairment Not recommended for use in Clcr <30 mL/minute or ESRD (contraindicated in Canadian labeling). In mild-moderate impairment, lower initial doses may be considered with titration guided by response and tolerability. Dosing: Hepatic Impairment Not recommended for use in hepatic impairment (contraindicated in Canadian labeling). |